Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies

Novartis's CEO divests some duties but keeps joint role

This article was originally published in Scrip

Executive Summary

Novartishas appointed Dr Joerg Reinhardt chief operating officer in a move that is intended to allow the company's chairman and CEO Dr Daniel Vasella to focus on the company's strategic aims. Dr Reinhardt was previously head of vaccines and diagnostics and will be replaced by Dr Andrin Oswald, who is currently CEO of the recently acquired Speedeland global head of pharmaceutical development franchises.

Table

View full table

Topics

Related Companies

Tags:
Companies
Latest Headlines

Pipeline Watch: Eighteen Approvals And Six Phase III Trial Updates

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

See All
UsernamePublicRestriction

Register

SC030580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By